Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Hollevoet, K. Nackaerts, J. Van Cleemput, J. Thimpont, P. De Vuyst, L. Bosquée, J. Delanghe, J. van Meerbeeck (Kapelle-op-den-Bos, Brussels, Leuven, Liège, Belgium). Screening of asbestos-exposed individuals using mesothelioma biomarkers. Eur Respir J 2010; 36: Suppl. 54, 3684

Member's Comments

No comment yet.

Related content which might interest you: Soluble mesothelin as an early diagnostic tool in asbestos-exposed workers Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Pleural plaques and the risk of lung cancer in a french cohort of asbestos-exposed subjects Source: Annual Congress 2013 –Occupational respiratory diseases: asthma, silicosis and asbestosis Year: 2013 Screening and diagnosis of lung cancer Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer Year: 2013 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Inter-reader variability of asbestos-related abnormalities reported on CT-scan in asbestos-exposed subjects Source: Eur Respir J 2007; 30: Suppl. 51, 158s Year: 2007 Lung cancer and pleural mesothelioma Source: Eur Respir Monogr 2014; 65: 48-60 Year: 2014 A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions Source: Eur Respir J 2013; 41: 18-24 Year: 2013 Lung function in patients with benign asbestos related pleural disease Source: Eur Respir J 2003; 22: Suppl. 45, 185s Year: 2003 Evaluating the utility of mesothelin in diagnosing mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Chemical characterization of exhaled breath to discriminate patients with malignant pleural mesothelioma from subjects with similar professional asbestos exposure Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions Year: 2010 Soluble mesothelin as a monitoring tool for malignant mesothelioma patients Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours Year: 2009 Breathlessness in subjects with asbestos-related pleural plaques Source: Eur Respir J 2002; 20: Suppl. 38, 127s Year: 2002 Study of NF2 and P16/CDKN2A genes in lung cancer in patients occupationally exposed to asbestos Source: Eur Respir J 2004; 24: Suppl. 48, 146s Year: 2004 Mesothelioma risk due to erionite exposure and genetic susceptibility to mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 455s Year: 2006 Volatile organic compounds increase the likelihood of detecting malignant pleural mesothelioma Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Prevalence of assessable asbestos deposit in patients with lung cancer Source: Annual Congress 2008 - Inorganic dust exposure and the lung Year: 2008 Proportion of patients with malignant pleural mesothelioma whose asbestos body numbers in the lung are equal to general population Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Outcomes of cytology positive malignant pleural effusions; do certain malignancies predispose patients to trapped lung? Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019